We at UCSF take your care seriously. Click here for COVID-19 information

University of California San Francisco

Clinical Trials

Slide

Our department is involved with some of the most important and innovative clinical trials in radiation oncology.

Clinical trials give patients access to the most advanced treatments to conquer their cancer and improve their lives. Our team learns about our patients’ needs and develops these new treatments. They are then tested in clinical trials.

Some of the most important trials ever completed in radiation oncology have been led by UCSF doctors.  The largest trials in patients with head and neck and prostate cancers were designed and led by our doctors. As a leading research institution, UCSF continues to innovate and run cutting edge clinical trials to improve the lives of our patients with cancer.

Jamese Johnson

Contact for UCSF Radiation Oncology clinical trials:
Jamese Johnson, MPH, CPH

Clinical Research Manager
Department of Radiation Oncology
Helen Diller Family Comprehensive Cancer Center
Email: jamese.johnson@ucsf.edu
Phone: 415-476-3048 

Current Trials

Principal Investigator Study Title Disease Status

Steve Braunstein, MD, PhD

Ride to care

Eliminating transportation barriers for disadvantaged cancer patients undergoing RT

All Open

Catherine Park, MD

FABREC

Study of Radiation Fractionation on Patient Outcomes After Breast Reconstruction for Invasive Breast Carcinoma

Breast Cancer Open

Anthony Wong, MD, PhD

FORMULA-509

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management

Prostate Cancer Closed

Anthony Wong, MD, PhD

RTOG 3506

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features

Prostate Cancer  Open

Osama Mohamad, MD, PhD

GU 008

Randomized Phase III Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy

Prostate Cancer Opening early 2021

Sue Yom, MD, PHD

NRG-HN001

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).

Head & Neck Cancer Open

Sue Yom, MD, PhD

Nivolumab +  ChemoRT for Patients with Nasopharyngeal Cancer

Nasopharyngeal Cancer Open

Sue Yom, MD, PhD

A Phase 1/2 Trial of Concurrent RT, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Head and Neck Cancer Open

Sue Yom, MD, PhD

HN004

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Head and Neck Cancer Open

Sue Yom, MD, PhD

HN005

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Head and Neck Cancer  Open

Sue Yom, MD, PhD

PembroX

Enhancing the Immunogenicity of Non-Small Cell Lung Cancer with Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study with Correlative Biomarkers

Lung Cancer  Open

Steve Braunstein, MD, PhD

METIS

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Lung Cancer Open

Sue Yom, MD, PhD

RTOG 1216

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Head and Neck Cancer  Open

Mary Feng, MD

ARM-GI

Phase II study of hypofractionated radiation therapy to Augment immune Response in patients with Metastatic GastroIntestinal malignancies progressing on immune therapy

GI cancers Open

Mary Feng, MD

Phase II Trial

Palliative Hypofractionated Radiotherapy Followed by Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Progression on Prior PD-1 Inhibition

Liver Cancer Opening early 2021

Mary Feng, MD

DECREASE

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma

Anal cancer Opening early 2021

 

For more information about clinical trials: http://www.clinicaltrials.gov/ct/info/whatis#whatis